Summary of Study ST000115

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000104. The data can be accessed directly via it's Project DOI: 10.21228/M80W2M This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000115
Study TitleImpact of insulin deprivation and treatment on sphingolipid distribution in different muscle subcellular compartments of streptozotocin-diabetic C57Bl/6 mice
Study TypeInsulin depravation
Study SummaryExperiments were conducted using 13-wk-old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME). Mice were housed individually with free access to water and chow (TD.10112; Harlan Laboratories, Indianapolis, IN), with a 12:12-h light-dark cycle and temperature and humidity control. Mice were acclimated for 1 wk prior to the beginning of the experiment. The protocol was approved by the Mayo Clinic Institutional Animal Care and Use Committee. Following a 6-h fast, mice were given intraperitoneal injections of STZ (125 mg/kg; in sodium acetate buffer, pH = 4.5) (67). Injections were repeated on the following day. Control animals received intraperitoneal injection of vehicle. Only mice that displayed blood glucose ?300 mg/dl and an increase in blood ketones (both values by Precision Xtra glucometer; Abbott Laboratories, Abbott Park, IL), hyperphagia, and polyuria and were positive for urine glucose presence via dipstick (Uristix, Bayer, Pittsburgh, PA) on day 7 after the first STZ dose were included in the experiment. Animals that were positive for STZ diabetes received LinBit subcutaneous insulin implant (LinShin Canada, Toronto, ON, Canada) (79) under pentobarbital sodium anesthesia (Nebutal, 40 mg/kg of body wt) according to the manufacturer's protocol. Each animal received two subcutaneous implants (total dose: 0.2 U/24 h for >30 days, 10 U/kg for 20-g mice). Insulin treatment was continued for 3 wk. Control animals (C; n = 13) received blank implants. Diabetic control was confirmed by biweekly measurements of blood and urinary glucose. In some cases, when urine glucose was present and blood glucose was >288 mg/dl, the animal received a third implant. The insulin treatment was continued until initially lower plasma glucose content in diabetic animals reached control values. Three weeks following implantation, diabetic mice were divided randomly into diabetic-treated (D + I; n = 13) and diabetic-deprived (D ? I; n = 13) groups. Insulin implants were removed from the D ? I group under pentobarbital anesthesia, which led to the return of the diabetic phenotype within 24 h. Animals from the D + I group continued on insulin treatment (Fig. 1). At the age of 18 wk, animals from all groups were analyzed for body composition by an Echo-MRI Body Composition Analyzer (EchoMRI, Houston, TX) and euthanized by decapitation 5 wk after the initial STZ or vehicle dose. Figure 1 depicts the timeline of the experiment and blood glucose profiles for each experimental group. Additional animals were used for estimation of skeletal muscle insulin sensitivity by acute insulin stimulation. The mice were divided into the C (n = 6), D ? I (n = 7), and D + I (n = 7) groups and followed appropriate experimental treatment, except for acute insulin stimulation 10 min prior to euthanization by pentobarbital overdose. Figure 1 of the attached PDF of the article summarizes the study design
Mayo Clinic
Last NameNair
First NameSreekumaran
Submit Date2014-09-30
Num Groups3
Total Subjects39
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Uploaded File Size24 M
Analysis Type DetailLC-MS
Release Date2015-02-03
Release Version1
Sreekumaran Nair Sreekumaran Nair application/zip

Select appropriate tab below to view additional metadata details:


Subject type: Animal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA006110D+32diabetic treated
SA006111D+52diabetic treated
SA006112D+24diabetic treated
SA006113D+21diabetic treated
SA006114D+14diabetic treated
SA006115D+23diabetic treated
SA006116D+70diabetic treated
SA006117D+57diabetic treated
SA006118D+58diabetic treated
SA006119D+53diabetic treated
SA006120D+56diabetic treated
SA006121D+55diabetic treated
SA006122D+54diabetic treated
SA006123D-69diabetic untreated
SA006124D-68diabetic untreated
SA006125D-41diabetic untreated
SA006126D-36diabetic untreated
SA006127D-39diabetic untreated
SA006128D-33diabetic untreated
SA006129D-31diabetic untreated
SA006130D-25diabetic untreated
SA006131D-28diabetic untreated
SA006132D-40diabetic untreated
SA006133D-42diabetic untreated
SA006134D-63diabetic untreated
SA006135D-64diabetic untreated
SA006136D-61diabetic untreated
SA006137D-60diabetic untreated
SA006138D-43diabetic untreated
SA006139D-67diabetic untreated
Showing results 1 to 44 of 44